The US filing for rheumatoid arthritis (RA) of Gilead Sciences Inc. and Galapagos NV's closely watched filgotinib is now expected by the end of this year, allaying fears that the drug would be at a competitive disadvantage to AbbVie Inc.’s already-submitted rival JAK inhibitor upadacitinib.
Gilead has announced that it has held a pre-submission meeting with the US Food and Drug Administration to provide an update about filgotinib, an oral, selective JAK1 inhibitor, and discussed the positive Phase III FINCH program